Arylenediamine acceptor properties and crown ether size affect the stoichiometry and supramolecular structure of co-crystals by means of restructuring of guest–host and guest–guest contacts, changing packing enthalpies and bonding energies.
The supramolecular aggregation of drug and co-former after co-crystal dissolution influences the taste of the material and offers a route to taste-masking of bitter drugs.
This perspective highlights the need for an inclusive regulatory definition and touches upon some fundamental crystal-engineering aspects and considerations useful for the design and development of pharmaceutical co-crystals.
A high-throughput nanoscale co-crystallisation approach is presented, that combines automation and small scale to enable the exploration of co-crystallisation conditions, resulting in 30 new binary, ternary and quaternary co-crystals.
Molecular set transformer is a deep learning architecture for scoring molecular pairs found in co-crystals, whilst tackling the class imbalance problem observed on datasets that include only successful synthetic attempts.